All In MedTech

Device Trial Radar · NCT07390344

VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

Jul 20, 2026

Primary completion

Sep 30, 2029

Study completion Sep 30, 2029

Sponsor

Lead sponsor
W.L.Gore & AssociatesNot on our public-company list
Sponsor type
Industry
First posted
Feb 5, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Registry will look at patients being treated with a transjugular intrahepatic portosystemic shunt (TIPS) procedure for portal hypertension. The purpose of this Registry is to collect data on the safety and performance of the GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm) for 2 years in real world setting. Additionally, data will be collected on the safety and performance of the GORE TIPS Set when utilized.

Conditions

  • Ascites
  • Variceal Bleeding
  • Portal Hypertension Related to Cirrhosis

Interventions

  • GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm)Device

    The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm) was developed and approved for the treatment of portal hypertension and its complications such as bleeding from enlarged or swollen veins (variceal bleeding) and abnormal build-up of fluid in the abdomen that does not respond to therapy (ascites which recurs despite conventional treatment). The Registry Device is a small tube (stent) that creates a pathway for blood flow. It consists of a metal frame (nitinol), covered with a thin, flexible material called expandable polytetrafluoroethylene (ePTFE).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects achieving primary patency through 2 yearsTime frame: Shunt primary patency will be analyzed at 1, 3, 6, 12 and 24 months.

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Emory University Hospital

    Atlanta, Georgia · Recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.